F
Fate Therapeutics, Inc.
FATE · NASDAQ · Healthcare · 300M
Closing price
$2.18
+2.35% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
1.2×
Enterprise value / EBITDAEV/EBITDA
-2.3×
Free cash flow yieldFCF yield
-43.3%
Return on equityROE
-65.8%
Operating margin
-2222.4%
Net debt / EBITDAbalance-sheet strength
-0.2×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.